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Recent reports have demonstrated ketamine’s potential use in the treatment of major depressive 
disorder (MDD), as it elicits potent antidepressant effects via a different mechanism compared 
to conventional antidepressants. Ketamine’s hypothesized antidepressant effect is elicited by a 
neurochemical cascade involving the antagonization of the N-methyl-D-aspartate  (NMDA) 
receptors and the subsequent activation of the α-amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid (AMPA) receptors; resulting in the disinhibition of glutamate signalling due to 
the suppression of tonic glutamate input into the GABAergic interneurons, providing rapid 
symptomatic relief as opposed to the two-week delay with conventional treatments. There is a 
large escalation in the number of individuals being diagnosed with treatment resistant 
depression (TRD) even after numerous trials on conventional antidepressant therapy. Health 
care professionals are now resorting to unconventional treatments, such as ketamine’s off-label 
use, to achieve therapeutic outcomes and provide symptomatic relief. MDD’s increasing 
prevalence has been associated with significant public health costs and morbidity rates and 
therefore alternative, effective treatments are now essential. Many reports have been published 
on the intranasal (IN) efficacy of ketamine in the treatment of major depressive disorder, 
however there have been no studies investigating the effects on the route of administration in 
drug delivery to the brain. 
The purpose of this study was to investigate pharmacokinetics of ketamine following oral, 
intraperitoneal and intranasal administration. A dose of 15mg/kg (body weight) was 
administered to healthy male Sprague-Dawley rats, and ketamine concentrations were 
quantified in both plasma and brain tissue homogenates at time intervals of 5, 15, 30, 60, 120, 
240 minutes post-treatment.  
The results showed that with intraperitoneal administration, concentrations of 524,58 ng/mL 
and 352,06 ng/mL, were achieved in plasma and brain tissue, respectively. Surprisingly, IN 
administration which is believed to favour drug delivery to the brain only exhibited moderate 
levels post administration; whereas, oral administration produced significantly lower levels due 
to extensive first-pass metabolism of ketamine in the liver and intestines. 
These results show that parenteral administration should be used for the administration of 
ketamine in the treatment of MDD. The findings of the study provide a platform for future 
investigations assessing alternative routes of administration of ketamine; and its use in clinical 
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 THESIS OUTLINE 
This project consists of: 
• Chapter One, the introduction to the use of ketamine for the treatment of major depressive 
disorder and theory behind the instrumentation used for this study. 
• Chapter Two, the results of this study which was submitted for publication, and 
demonstrate the pharmacokinetics of ketamine through intranasal, oral and intraperitoneal 
administration. The LC-MS method for the simultaneous quantification of ketamine in rat 
plasma that was developed. 
• Chapter Three, A summary of the work done, which is inclusive of limitations and 






















CHAPTER 1: INTRODUCTION 
1.1 MAJOR DEPRESSIVE DISORDER (MDD) 
Major Depressive Disorder (MDD) is an incapacitating mental disease, with a lifetime 
incidence of 16.2% [1, 2]. It is predicted to be amongst the leading causes of the global disease 
burden in the industrialized world by 2020 , compromising the overall quality of everyday life 
in affected individuals [1,2].  The symptoms of MDD are hypothesized to arise from a 
combination of environmental, inherent and genetic factors [4, 5]. Major Depressive Disorder 
is characterized by abnormalities in mood and affect, contracted interest, impaired cognition, 
vegetative symptoms such as insomnia and weight loss, in addition to diminished psychomotor 
activity; with episodes usually lasting for two weeks or more [1, 4, 5]. Diminished cognitive 
capacity is a fundamental endo-phenotype of MDD [8]. The disruptions in cognition have been 
attributed to well documented abnormalities in the dorsolateral prefrontal cortex (DLPFC), 
hippocampus and medial temporal lobe of MDD patients [9]. In a study conducted on animals 
subjected to various stressors for a period of time, atrophy of the hippocampal regions of the 
brain were observed which is similar to neurological changes seen in patients with depression 
[10]. Impairment of hippocampal functioning, as well as the capability for neuroplasticity could 
contribute to several of the pathophysiological characteristics of MDD [11, 12]. 
 A small population of patients with MDD may experience manic episodes which are 
characterized by euphoria, hyperactivity and pleasure seeking in comparison to unipolar 
depression [10, 11]. Treatment approaches consist of both psychological and pharmacological 
interventions, as well as social and lifestyle modifications [15]. The current diagnostic criteria 
for MDD involves clinical and historical background on the more prominent symptoms and 
signs experienced by the patient, however affected individuals exhibit an extensive variety of 
clinical symptoms and signs making diagnostic conventions subjective [16]. Major Depressive 
Disorder is a heterogenous psychological disease with no definitive causation; however, 
gender, specific personality characteristics, stressful life circumstances, genetics and  negative 
childhood experiences are risk factors closely associated with the incidence of MDD [4, 9, 11]. 
The correlation between a dysregulated stress response or chronic stress accompanied by 
behavioral and molecular changes that exhibit a depressive state has become increasingly more 
evident [11].  
A significant percentage of patients with MDD experience their first episode during childhood 
and adolescence [16]. In these circumstances these individuals continue to experience recurring 




experience a chronic unremitting course and may also exhibit significant deficits in memory, 
necessitating the need for long-term prophylactic treatment [4, 9]. 
The pathophysiology of depression remains an elusive topic; however, studies suggest the 
involvement of serotonergic, dopaminergic and noradrenergic pathways [4]. Serotonergic and 
noradrenergic receptor systems are located deep in the brain and spread out over almost the 
entire brain [13]. These systems are hypothesized to be responsible for modulating thought, 
behavior and emotions [13]. Inhibition of the reuptake of these neurotransmitter pathways at 
the synapse results in an increase in postsynaptic neuron stimulation; resulting in the 
development of antidepressants targeting either one or all monoamines [19]. These findings led 
to the construction of the monoamine-deficiency hypothesis (Figure 1), which suggests that the 
primary symptoms of depression are due to insufficient levels of monoamine neurotransmitters, 
notably norepinephrine (NE) and serotonin (5-HT) in the brain [9, 12, 13] . These depletions 
could result from abnormalities in synthesis, metabolization, storage and reuptake processes; 
or receptor abnormalities irrespective of  normal monoamine levels [1]. While this theory has 
provided extensive insight in the treatment of MDD; studies suggest that MDD surpasses 
monoaminergic depletion as its primary pathophysiological mechanism [1]. Therefore, recent 
studies suggest other mechanisms that contribute to the development of MDD; such as 
neurotrophins, gene expression and synaptic plasticity[1, 2].  Synaptic plasticity is the dynamic 
ability of the synapse generation and retraction processes; therefore modulating synaptic 
communication and strength [22]. Decreased synaptic plasticity and neurogenesis has a 





Figure 1: Depression caused by Neurotransmitter Deficiency. NE:norepinephrine, 5-HT: Serotonin, Dopamine 
neurotransmissions is hindered due to receptor abnormalities preventing post-synaptic binding. 
1.2 CURRENT ANTIDEPRESSANT TREATMENTS 
Successful treatment of depressive symptoms in patients with treatment resistant depression 
[TRD] has been a challenge for almost 100 years, in which many treatment regimens and other 
practices have been employed in an attempt to provide sufficient relief and regulations of 
depressive symptoms [1]. The somatic treatment of depression began in the 1920s and since 
then many advancements have contributed to treating depression [1].  
1.2.1 Tricyclic Antidepressant (TCAs) 
Tricyclic Antidepressants were founded in the 1950s and named, based on their structures 
(Figure 2); TCAs has provided a platform for the development of later drugs for the treatment 
of depression [1]. The mechanism of action of TCAs is complex but its therapeutic action is 
primarily by inhibition of the serotonergic, dopaminergic and noradrenergic pathways reuptake 




antagonism of the histamine (H1) receptor [23]. A comprehensive understanding of the exact 
neurochemical mechanism remains elusive; as TCAs produce a variety of biochemical effects 
[24]. TCAs are rapidly absorbed following oral administration and bind extensively to plasma 
albumin at therapeutic concentrations [25]. They also bind to extravascular tissue which may 
account for its relatively large distribution volumes [25]. The bioavailability  varies among the 
different TCAs, with amitriptyline, imipramine and protriptyline ranging between 30-60%, 30-
75%, 76-90% respectively [26]. The use of TCAs for the treatment of depression is associated 
with low acceptability and tolerability due to their side effects and that is why they are less 
frequently prescribed nowadays [27]. Common side effects experienced with the use of TCAs 
is sexual dysfunction, dizziness, drowsiness, cardiovascular effects and more rarely behavioral 
(pacing, confusion, memory impairment, agitation)  or cognitive toxicity [1, 9] Some TCAs 
such as amitriptyline are employed in the management of chronic pain syndromes; such as 
post-herpetic neuralgia, diabetic neuropathy, atypical facial pain and fibromyalgia [24]. 
Growing evidence of interaction with other drugs and especially those involving cytochrome 
P450 (CYP450) inhibition with TCAs necessitates careful consideration of the usefulness of 
TCAs in the treatment of depression, especially in relation to newer drugs [25]. However, 
findings in a meta-analyses states that TCAs are more effective in the treatment of severe 
depression than SSRI’s due to their dual action on serotonin and norepinephrine receptors as 
opposed to the selective nature of SSRI’s [28]. Therefore, TCAs still have their place in 
treatment of depression, the disadvantages and risks associated with their use have been 
exaggerated when compared to newer drugs [25]. 
 
Figure 2: General Structure of Tricyclic Antidepressants 
1.2.2 Monoamine Oxidase Inhibitors 
Monoamine Oxidase is an enzyme that is found in two isoforms, A and B; with isoform 
Subtype A being involved in affective disorders due to its higher affinity for noradrenaline and 
serotonin [29]. Monoamine Oxidase Inhibitors are classified based on their selectivity for an 




with the use of MAOIs as they cause inhibition of enzyme activity resulting in non-specific 
increases in synaptic monoamines, therefore caution is necessary with their use [31].With older 
drugs strict dietary restrictions are required especially with tyramine or tryptophan rich foods 
and circumvention of serotonergic drugs,  as concomitant use with  MAOIs may cause 
serotonin syndrome or a hypertensive crisis (‘cheese reaction’) , due to the sudden increase in 
monoamine transmitter availability and impaired synaptic clearance with the enzyme inhibition 
[32]. Reversible MAOIs such as Moclobemide (Figure 3), selectively inhibit isoform A of the 
enzyme; resulting in an increase in serotonin and noradrenaline without markedly affecting the 
degradation of tyramine [30]. Non-selective MAOIs such as Tranylcypromine act by 
irreversible inhibition of the enzyme; resulting in an increase in biogenic amines such as 
noradrenaline, serotonin and dopamine in both the periphery and brain [30]. This type of 
MAOIs are not used frequently because of its higher affinity of leading to a hypertensive crisis 
when combined with certain foods and medicines [30]. Monoamine Oxidase Inhibitors are 
therefore reserved for  the treatment of TRD, atypical depression and specific forms of bipolar 
depression [33]. 
 
Figure 3: Molecular Structure of Moclobemide 
1.2.3 Selective Serotonin Reuptake Inhibitors (SSRIs) 
The development of SSRIs has transformed  psychiatric therapy; making them the most 
frequently prescribed antidepressants of today [1]. Its working mechanism involves the 
blocking of serotonin re-uptake at pre-synaptic neurons by inhibition of membrane serotonin 
transporter proteins [30]. Upon repeated dosing SSRIs are able to preserve their selective nature 
and potent inhibition of serotonin reuptake [34]. SSRIs effectiveness in the treatment of 
depression does not vary to that of TCAs; however, they are preferentially used due to their 
unequivocally superior tolerability and safety, due to fewer anticholinergic and cardiovascular 
effects [19, 22]. Their advantageous tolerability and safety profile plays a significant role in 
the improvement of compliance and is consequently cost effective in the long run [36]. 
However, even though SSRIs exhibit superior clinical benefits the structural diversity of this 
group results in a variety of potential side effects such as sleep deprivation, sexual dysfunction 
and more seriously suicide ideation, drug interactions and variations in pharmacological and 




when compared to other SSRIs, resulting in side effects and drug interactions that may 
potentiate, long after, treatment has ceased [36].   
 
 
Figure 4: Molecular Structure of Fluoxetine 
1.2.4 Alternative treatments 
Serotonin Noradrenaline Reuptake Inhibitors (SNRIs) such as Venlafaxine and Duloxetine 
(Figure 5), activity is based on dual reuptake inhibition as it blocks the reuptake of 
noradrenaline and serotonin by inhibiting their transporter proteins [37]. These agents have a 
higher tolerability and safety profile that is comparable to that of SSRIs due to their chemical 
specificity [37]. 
                   
 
Figure 5: Serotonin Noradrenaline Reuptake Inhibitors 
Tetracyclic antidepressants such as Maprotiline and Mianserin (Figure 6) are closely related to 
tricyclic antidepressants; sharing a lot of properties as well as limitations with their use in the 
treatment of depression, especially cardiovascular complications [38]. However, Mianserin 
does not inhibit the reuptake of noradrenaline when compared to their tricyclic counterparts; 
but works by blocking presynaptic alpha receptors, enhancing the turnover of noradrenaline in 







Figure 6: Molecular Structure of Mianserin 
Noradrenergic and specific serotonergic agents such as Mirtazapine (Figure 7), act centrally by 
causing presynaptic alpha antagonization; subsequently increasing central noradrenergic and 
serotonergic neurotransmission [30]. 
 
Figure 7: Molecular Structure of Mirtazapine 
Serotonin Re-uptake Inhibitors and receptor antagonist (Trazodone (Figure 8)) does not 
influence the reuptake of noradrenaline peripherally but rather indirectly facilitates neuronal 
release [30]. Its primary activity is based on the inhibition of the reuptake of presynaptic 
serotonin as well as serotonin 5HT1 activity [30]. 
 
Figure 8: Molecular Structure of Trazodone 
Dopamine Re-uptake Inhibitors (Bupropion (Figure 9)) mechanism of action is primarily by 
inhibition of dopamine reuptake with weak serotonin and noradrenaline reuptake inhibition. 





Figure 9:  Molecular Structure of Bupropion 
1.3 KETAMINE  
Ketamine (RS-2-2-Chlorophenyl-2-methylamincyclo-hexanone) is clinically approved to be 
used as an anesthetic and analgesic; however, there is growing off-label use of ketamine in the 
treatment of depression at a sub-anesthetic dose, particularly in TRD [7,8]. Ketamine (Figure 
10)  is primarily utilized in veterinarian pharmacotherapy and occasionally in paediatrics [1]. 
It can be administered intranasally via snorting or inhaling as a powder, orally, and by 
intravascular or intramuscular injection [1]. A single infusion of ketamine sufficiently relieves 
patients that are symptomatic within hours; and is effective for an extensive period, however, 
the duration of the antidepressant effects of ketamine varies across studies with most patients 
experiencing relief for 72 hours or longer [7, 10]. In a trial on the antidepressant effects of 
ketamine, most patients experienced mood elevation approximately 120 minutes post- infusion 




Figure 10: Molecular Structure of Ketamine 
1.3.1 Ketamine’s use in Depression 
Approximately two-thirds of patients with MDD do not receive sufficient relief from 
conventional antidepressant treatments; and as many as one-third of these patients remain 
untreated after numerous trials of antidepressants [15]. Patients diagnosed with Treatment 
Resistant Depression (TRD) are defined as being unresponsive to two or more trials of 
antidepressants [22]. Given the heterogenous pathophysiology of MDD a number of 
environmental, patient specific characteristics, and the nature of the depression, contributes to 
how the patient responds to treatment [40]. Patients with TRD experience extensive debilitation 
in social, economic and personal aspects, and are more likely to exhibit suicide ideation [15]. 
Moreover, the two week delay that is associated with the use of conventional antidepressants 
is of particular concern in patients with continuous suicidal ideation [22]. Thus, the pressing 







symptoms and at the same time maintain antidepressant therapeutic effects; this partly accounts 
for the use of ketamine in the treatment of depression [15]. 
The current hypothesized mechanism of action of ketamine in the treatment of depression is 
based on a neurochemical cascade. Ketamine antidepressant effect is produced via the 
antagonization of the N-methyl-D-aspartate receptors (NMDARs) and the subsequent 
activation of the α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors 
(AMPARs). N-methyl-D-aspartate receptors are widely distributed throughout the cortical and 
subcortical areas in the brain [1]. Synaptic plasticity and neurogenesis depletion have a 
significant influence on the pathophysiology of MDD. Synaptic plasticity is a biological 
process in which specific patterns in synaptic activity results in the modifying of the 
communication and strength of the synapse based on its ability to retract and form [22]. 
Plasticity is most commonly mediated by long-term potentiation (LTP) and long-term 
depression (LTD) mechanisms that involve extensive alterations in both pre- and post-synaptic 
glutamate receptors (primarily glutamatergic receptors such as NMDA and AMPA) and 
scaffolding proteins [22]. Long-term potentiation is associated with the GluR1, GluR4,and 
GluR2 subunits of the AMPA receptor whereas the GluR2, GluR3, and GluR4 subunits are 
involved in internalization of the receptor, required for LTD [22]. During the LTD the NMDA 
receptors at the excitatory synapses are significantly reduced and subjected to trafficking [22]. 
Ketamine antagonizes the pre-synaptic NMDARs signalling which results in the disinhibition 
of glutamate signalling due to the suppression of tonic glutamate input into the GABAergic 
interneurons [22]. A decrease in GABAergic inhibitory feedback of the pyramidal neurons that 
are in the Layer V of the Prefrontal cortex (PFC) mediates the subsequent increase in glutamate 
due to the antagonization of the NMDARs [22]. Glutamate is the most prevalent excitatory 
neurotransmitter that is found in the subcortical and cortical parts of the brain; it is an amino 
acid that is produced from glutamine via the glutaminase enzyme and released usually from 
voltage-gated calcium channels [1, 38]. Glutamic acid decarboxylase converts glutamate into 
an inhibitory neurotransmitter known as Gamma-Aminobutyric Acid (GABA) whereas 
glutamine synthetase reduces glutamate to glutamine [1]. Glutamate effects are antagonized by 
the activity of glutamate transporter proteins at the synapse; which triggers the reuptake and 
metabolism of the amino acid, maintaining extracellular homeostasis [1]. Glutamate 
homeostasis plays a significant role in maintaining synaptic plasticity hence the necessity for 
the pathway to be closely regulated [1]. Too little glutamate results in an impairment in synaptic 




damage[1]. Glutamate is involved in many processes regarding emotion and cognition [42]. 
This enhanced glutamate signaling due to pre-synaptic NMDARs antagonization results in the 
subsequent activation of the AMPARs and the consequential cell depolarization activates the 
voltage sensitive calcium channels [43]. This results in the influx of calcium and Brain-derived 
Neurotrophic factor (BDNF) exocytosis. BDNF stimulates the Tropomyosin Receptor Kinase 
B (TrkB) as well as other signalling pathways downstream such as the MEK-Erk1/2 PI3K-Akt 
pathways. These pathways lead to the activation of the Mammalian Target of Rapamycin 
(mTOR) complex 1 via phosphorylation [43]. Subsequently this activates the Ribosomal 
protein S6 kinase (p70S6K) which results in the inhibition of Eukaryotic  elongation factor-2 
kinase (eEF2K), stunting eEF2 phosphorylation and consequentially inhibiting it [43]. 
Simultaneously translation repressor protein  4E-binding protein 1 (4E-BP1) is 
hyperphosphorylated by mTOR, diminishing the interaction with Eukaryotic translation 
initiation factor 4E (eIF4E) [43]. The combination of  the release of eIF4E  from 4E-BP1  and 
decreased phosphorylation of eEF2 results in the disinhibition of protein translation resulting 
in enhanced production of  synaptic  proteins such as PSD95, Arc, synapsin I, BDNF and 
GluR1 [43]. This enhances synaptogenesis and dendritic spine density in the PFC and 
hippocampus as these proteins are significantly involved in the function, formation and 
maturation of new spine synapses; therefore producing anti-depressant-like behaviour [43]. 
Ketamine also regulates other neurotransmitter pathways, such as the striatal and nucleus 
accumbens release, GABAergic activity, serotonin and noradrenaline transporter proteins and 
dopamine [1]. This neurochemical cascade leading to the antidepressant effects of ketamine is 





Figure 11: Diagrammatic representation of the mechanism of action of Ketamine. Putative signalling pathways results in 
NMDAR signalling resulting in subsequent glutamate release which activates post-synaptic AMPAR resulting in a 
neurochemical cascade eliciting antidepressant activity. 
1.3.2 Pharmacokinetics and bioavailability of ketamine 
Numerous factors can influence the pharmacokinetic profile of a drug, including age, gender, 
nutritional status, environmental conditions and disease states [41, 42]. Ketamine exhibits a 
chiral structure that comprises of two optical isoforms [46]. The S(+)-enantiomer is the 
preferred form due to it being four times more potent that the R(-)-enantiomer; and twice as 
much more effective than ketamine’s racemic mixture [46].  
Ketamine is metabolised primarily to Nor-ketamine in the body by cytochrome P450, 3A and 
2B6 enzymes via oxidative metabolism; with approximately 90% excreted via the kidneys  
after extensive hepatic metabolism [30–32]. 
Oral bioavailability of ketamine is reduced significantly due to the extensive first-pass 
metabolism of ketamine in the body; therefore, other routes of administration such as 
sublingual and intranasal formulations are being developed [46]. Intranasal (IN)  and 
intramuscular (IM) formulations of ketamine produce maximum plasma concentrations rapidly 
post-administration, with comparatively high bioavailability [30, 32]. In a randomized 
controlled trial of intranasal administration of ketamine it was found that patients had 
significant improvements in symptoms and tolerability after 24-hours of ketamine 
administration [49].  Findings in a study on healthy human volunteers at an analgesic dose, 
showed that the absorption of ketamine following IM administration is rapid with a 





bioavailability of 93% [50]; whereas only 17% was absorbed following oral administration, 
due to extensive first pass metabolism [50]. 
Ketamine is well distributed and rapidly absorbed in the central nervous system [44]. The half-
life of ketamine varies in different species and is also dependant on age and route of 
administration. In a study conducted on Sprague-Dawley rats the half-life in young rats was 
approximately 1.3 hours whereas in aged rats 8.5-13 hours following IP administration of 
125mg/kg in three divided doses; indicating that drug clearance is markedly reduced with age 
[44]. Subsequently, the stagnation in clearance results in enhanced drug availability which is 
reflected by the AUC [44]. 
1.4 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY 
Following the initial studies conducted by J.J. Thomson (1912), Mass Spectrometry (MS) has 
undergone numerous improvements; and has revolutionized the analysis of non-volatile and 
volatile compounds [48, 49].  Mass spectrometry’s distinctive characteristics has made it one 
of the most exceptional and important analytical techniques used today for the determination 
of elemental concentrations, surface and isotope analysis and for the analysis of organic and 
bioorganic compound structures, due to its diversity of applications, speed, unsurpassed 
sensitivity, small sample volume analysis and low detection limits [35, 36].  
Mass Spectrometry was limited to thermostable and smaller compounds for a long time due to 
the deficiency of effective methods to softly ionize molecules and transfer these molecules 
from the condensed phase to the gaseous phase without unnecessary fragmentation [54]. In the 
late 1980s the development of two techniques, Electrospray Ionization (ESI) and Matrix 
Assisted Laser Desorption/Ionization (MALDI) for the systematic and general construction of 
molecular ions of intact biomolecules made it possible to analyze polypeptides by mass 
spectrometric methods [55]–[57]. 
This mainstream chemical analysis techniques uniqueness is attributed to its ability to directly 
detect molecules based on the mass-to-charge ratio as well as compound fragmentation patterns 
[58]. Firstly, the analyte of interest is introduced into the system and transferred to the source, 
in which ionization takes place [59]. Mass Spectrometry is more commonly associated with 
the separation of species that are electrically charged (ions)  when produced by the ion source 
in a gas phase [41, 42]. However, in some instances the ion source further assists the transfer 
of liquid-phase or solid-phase analytes into the gaseous phase [58]. Once in the gaseous phase 




or space) based on their mass-to-charge ratios (m/z) [36, 42]. The ion detector  subsequently 
detects the separated ions in the relative domain (space or time), producing electrical signals 
that are processed to generate a mass spectrum which may correspond to the original analyte, 
their fragments and other species produced during the ionization process [58]. 
 
Figure 12: Diagram illustrating the workflow of MS  (Adapted from [53] ) 
The development of electrospray ionization mass spectrometry (ESI-MS) as an ion source has 
contributed significantly to quantitative MS [41, 44]. Combined with High-Performance Liquid 
Chromatography (HPLC) it has become a useful tool for the analyses of various molecules in 
biological samples [61]. The ESI utilizes electrical energy to aid in the transfer of ions from 
the liquid phase into the gaseous phase prior to mass spectrometric analysis [62]. The process 
of the transfer of the ions into the gas phase occurs by (1) the dispersion of a fine spray of 
charged droplets which is followed by (2) solvent evaporation and (3) ion ejection from the 
charged droplets under high voltage relative to the enclosing chambers walls [61]. A fine mist 
of highly charged droplets is generated with a polarity that is the same to the capillary tube. 
The utilization of a nebulizing gas such as nitrogen enhances the sample flow rate [62]. The 
highly charged droplets exit the electrospray tip and move down a gradient (potential and 
pressure) towards the mass analyzer [62]. The charged droplets undergo size reduction when 
subjected to the ESI source temperature and nitrogen drying gas resulting in an increase in 
surface charge density and a reduction in the droplet radius. The generated electric field 
strength within the droplets make it possible for ions to be discharged into the gaseous phase 
[62].  However, ESI, is just one of the ionization techniques utilized in analytical techniques.  
Liquid Chromatography-Mass Spectrometry (LC-MS) is a technique that is now routinely 
used, especially when coupled with ESI [63]. This technique can be applied to a variety of 
biological samples and with the use of tandem MS and stable internal standards it enables the 
development of accurate and extremely sensitive assays, accompanied with method 
optimization [63]. The LC systems coupling with MS has always been desirable due to the high 
sensitivity and specificity nature of MS in comparison to other chromatographic detectors [63]. 
Introduction of 















A typical LC-MS system is the coupling of HPLC with MS; the sample is initially separated 
by LC, these separated species are thereafter introduced into the MS system [64]. In the HPLC 
system, solvent is pumped under high pressures through a column that is filled with solid 
adsorbent materials, allowing for separation of the analyte into different constituents and 
degrees based on its affinity for the columns material [65]. The sample is introduced into the 
system either by the autosampler or direct injection into the mobile phase stream that permeates 
through the column [64]. The different constituents of the sample travel at different speeds; as 
the velocity of the analyte is dependent on the compound’s nature and the composition of the 
mobile phase [48, 49]. The time at which the analyte elutes or emerges from the column is 
called the retention time. Various columns are available, loaded with various absorbents that 
vary based on molecule size, nature of their surface and chemical constituents [66]. The 
composition of the mobile phase may remain constant (isocratic elution mode) or changed 
(gradient elution mode) during the analysis. The choice of the mobile phase is dependent on 
the partiality of the analyte with the mobile phase and the stationary phase within the column 
[65]. 
Components of a LC-MS system 
The solvent reservoir contains the mobile phases that are used during the analysis. In HPLC 
the mobile phase is a mixture of non-polar liquid components and polar liquid components, 
depending on the chemical composition of the sample [65]. The sample injector injects the 
analyte into the mobile phase stream, in which a pump, suctions the mobile phase from the 
reservoir and forces it towards the column under high operating pressures. The pressure at 
which the pump operates is dependent on the column dimensions, flowrate and composition of 
the mobile phase and particle size. [46, 48] The sample is thereafter introduced into the column 
which is typically stainless steel, loaded with a stationary phase. Separation can be either in the 
reverse phase or normal phase mode of adsorption [64]. Normal phase separation involves a 
polar stationary phase and a non-polar mobile phase; whereas, reverse phase separation 
involves a non-polar stationary phase and a polar mobile phase [64]. The analyte is introduced 
into the mass spectrometric detection system in which it is ionized and thereafter a data 









Figure 13: LC-MS Instrumentation  (Adapted from [64] ) 
Rationale for the Study 
Quantification of ketamine in brain tissue and plasma enables health care professionals to 
develop treatment regimens that promote symptomatic relief, especially in patients with 
treatment resistant depression (TRD). The suffocating impact MDD has on the public health 
system and the progression to other mental conditions necessitates the development  of more 
effective treatment regimens. The findings of this study will improve the understanding on the 












1.5 AIMS AND OBJECTIVES 
The aim of this project was to quantify ketamine concentrations in rat plasma and brain tissue 
using LC-MS in order to understand it’s clinical use for the treatment of Major Depressive 
Disorder.  
The following objectives of the study were: 
1. The fundamental objective of the study is the quantification of ketamine in brain tissue 
and plasma using LC-MS. 
2. To determine tissue specific (brain) pharmacokinetics of Ketamine using LC-MS after 
intranasal, intraperitoneal and oral administration to determine the best route for 
effective treatment of MDD. 
3. To establish if these concentrations are adequate to enable more effective treatment of 
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Ketamine is approved by the FDA to be used as an anesthetic however, recent reports have 
exhibited its success in the treatment of major depressive disorder (MDD). Studies have 
suggested that a sub-anesthetic dose produces rapid antidepressant activity providing 
significant symptomatic relief particularly in patients with a history of treatment resistant 
depression (TRD). Many reports have been published on the intranasal (IN) efficacy of 
ketamine in the treatment of depression, however studies that have investigated the effects of 
the route of administration on drug delivery to the brain appear to be absent in literature. 
Therefore, in this study, a single dose (15mg/kg body weight) was administered via different 
routes of administration [oral (PO), intranasal (IN) and intraperitoneal (IP)] to healthy male 
Sprague-Dawley rats in order to determine the brain tissue pharmacokinetics of ketamine. A 
novel validated liquid chromatography-mass spectrometry (LC-MS) method was developed 
using a fused core column for the determination of ketamine in plasma and brain homogenates. 
While IP administration resulted in favorable concentrations in the brain and plasma; IN 
administration, which is supposed to favour drug delivery to the brain, exhibited moderately 
low drug levels post administration. PO administration produced significantly lower levels due 
to extensive first-pass metabolism in the liver and intestines. These results have implications 
for future studies exploring the use of ketamine for the treatment of MDD in order to optimize 
treatment regimens and suggest that parenteral administration of ketamine should be used in 
the treatment of depression. 
Keywords: Major Depressive Disorder, Ketamine, Antidepressant, Liquid Chromatography 
1| INTRODUCTION 
In the 1960s, ketamine (RS-2-2-Chlorophenyl-2-methylamincyclo-hexanone) was discovered 
to have analgesic and anesthetic effects with the potential to produce hallucinogenic and 
dissociative symptoms in individuals; however, recent studies have exhibited intranasal 
ketamine’s rapid and long lasting anti-depressive effects in patients with major depressive 
disorder (MDD) and more especially in those diagnosed with treatment resistant depression 
(TRD) [7], [39], [67], [68]. MDD’s increasing prevalence has been associated with significant 
public health costs and morbidity rates [4], [69]; the heterogeneity of this clinical disorder 
results in variations in symptoms experienced by individuals ranging from pervasive, low 
moods and loss of interest accompanied with more classical symptomology such as loss of 




[70]. The suffocating impact on the public health system arises as a result of the disorder having 
a greater propensity to originate in adulthood and continue as a chronic or recurrent condition 
into the later stages of life; diminishing the overall quality of life of those that are affected; and 
often resulting in devastating outcomes such as suicide ideation [70].  
Approximately two-thirds of patients with Major Depressive Disorder do not receive 
satisfactory relief from conventional antidepressant treatments; and as many as one-third of 
these patients are categorized as treatment resistant; and remain untreated after numerous trials 
of antidepressants [15]. In an attempt to resolve this escalating resistance to conventional 
antidepressants, medical practitioners have resorted to the off-label use of ketamine for the 
treatment of MDD [40]. 
A single dose of ketamine provides symptomatic relief within hours; and is effective for an 
extensive period, however, the duration of the antidepressant effects of ketamine fluctuates 
across studies and is dependent on the route of administration [15], [40]. In a trial on the 
antidepressant effects of ketamine, most patients experienced mood elevation approximately 
120 minutes post- infusion of ketamine [40]. Studies have also shown that a sub-anesthetic 
dose of ketamine (0.5mg/kg) over a 40-minute IV infusion produces rapid antidepressant 
activity in those diagnosed with TRD [71]. Ketamine’s hypothesized antidepressant effect is 
elicited by a neurochemical cascade involving the antagonization of the N-methyl-D-aspartate 
(NMDA) receptors and the subsequent activation of the α-amino-3-hydroxy-5-methyl-4-
isoxazole propionic acid (AMPA) receptors; resulting in the disinhibition of glutamate 
signalling due to the suppression of tonic glutamate input into the GABAergic interneurons 
[1], [22]. 
The route of administration of ketamine significantly affects its efficacy in the treatment of 
MDD [71]. Oral bioavailability of ketamine is significantly reduced due to the extensive first-
pass metabolism of ketamine in the body; therefore, other routes of administration such as 
sublingual and intranasal formulations are being investigated  [46]. Intramuscular (IM) 
formulations of ketamine produce maximum plasma concentrations rapidly post-
administration, with comparatively high bioavailability [46], [48]. In a randomized controlled 
trial of intranasal administration of ketamine it was found that patients had significant 
improvements in symptoms and tolerability after 24-hours of intranasal ketamine 




to its potential to cause psychedelic (panic attacks, hallucinations, memory defects), 
cardiovascular, neurological and hepatoxic side effects [72], [73].  
Currently, several trials have been conducted to determine the analgesic, anaesthetic and 
antidepressant effect of ketamine; however, the quantification of ketamine in the brain in order 
to elicit it’s antidepressant activity remains elusive [50], [67], [74]. In addition to several 
reports that have been published on the IN efficacy of ketamine in the treatment of depression, 
there have been no studies investigating the effects of the route of administration on drug 
delivery to the brain. Furthermore, considerable limitations occur in previously reported studies 
as methods employed for the determination of ketamine are costly and time-consuming; with 
extensively long analytical run-times [67], [75]. Therefore, the objectives of this study are to 
develop a rapid and sensitive method using a fused core column for the quantification of 
ketamine in rat plasma and brain tissue following to determine which route favours drug 
delivery to the brain.  
2| MATERIALS AND METHODS 
2.1| Chemicals and reagents 
Ketamine HCL solution (100mg/ml, Fresenius Kabi) and Ketamine D-4 HCL (0.1mg/ml) 
(DLD Scientific, Durban, South Africa) were obtained. Ammonium Acetate (10mM, pH 9.5) 
and LC-MS grade methanol (MeOH) were all procured from Sigma Aldrich (Steinham, 
Germany). Analytical Grade formic acid was purchased from Merck Millipore, South Africa. 
Solid-Phase extraction cartridges were purchased from Supelco-Sigma (St. Louis, MO) 
Ultrapure water was purified using a Milli-Q water purification system (Bedford, MA, USA). 
All Chemicals utilized in the study were of analytical grade. 
2.2| Chromatographic conditions 
Separation was performed on an Ascentisâ Express Biphenyl column (5cm x 2.1 i.d., 2.7 µm 
Particle size) with a Fused-Coreâ Particle design; and a gradient mobile phase changing from 
50% Millipore water (0.1% v/v formic acid) (A) and 50% methanol (B). The flow rate was set 
at 0.4 mL/min with an injection volume of  5µL; and a total run time of 7 minutes. 
2.3| Mass Spectrometry 
An Agilent series 1100 (Agilent technologies, Waldbronn Germany) was coupled to a maXis 
4G quadruple-time-of-flight Mass spectrometry instrument (Bruker Daltonics, Bremen, 




Quantitative studies were conducted using MS via an ESI interface with the following settings: 
drying temperature, 200°C; nitrogen nebulizer gas 0.4 bar; end plate offset, -500V; capillary, 
5500V and drying gas, 4.0 L/min. The collision energy was optimized to 12eV for Ketamine 
and the IS (ketamine D-4) to achieve the required selectivity and sensitivity for the method. 
The mass of Ketamine and the IS were m/z 238.1 and 242.1 respectively. 
2.4| Animals 
All experimental animal procedures involving handling and treatment were approved by the 
Institutional Animal Research Ethics Committee (AREC, UKZN) (approval Reference: 
AREC/003/018M). Fifty-four male Sprague-Dawley rats (weighing between 110-120g) were 
sourced from the University of Kwa-Zulu Natal Biomedical Resource Unit and were used to 
conduct the study. All animals where housed under appropriate ethical standards in a well-
ventilated room with humidity control systems, a 12-hour light/dark cycle and the 
recommended enrichment.  
2.5| Drug administration and sample collection 
Animals (n=3 in each route of administration (ROA) per time point) were administered 
15mg/kg body weight of ketamine-HCL via either intranasal (IN), oral (PO) or intraperitoneal 
route. Three animals per route were utilized as controls and received normal saline. Animals 
(n=3 per ROA ) were euthanized at 0 (control|); 5; 15; 30; 60; 120; and 240-minutes post 
administration via IsoFor (Safeline Pharmaceuticals, South Africa) overdose. Blood samples 
were collected via cardiac puncture; and brain tissue surgically removed post termination. 
Brain tissue samples were frozen gradually with liquid nitrogen vapor; biological samples were 
stored at -80°C until analysis.  
2.6| Method Validation 
2.6.1| Calibration and quality control preparation 
A primary stock solution of ketamine was prepared (10µg/10ml) in Ultrapure water and stored 
at -20°C. The lower limit of quantification (LLOQ), low quality control (LQC), medium quality 
control (MQC) and high-quality control (HQC) at 100ng, 250ng, 750ng and 2000 ng/ml were 
prepared from the stock; and spiked with IS at a concentration level of 750ng/ml. The 
calibration curve was prepared in triplicate (n=5) in a range of 100-2000 ng/mL. 
2.6.2| Linearity and lower limit of quantification 
The linearity of this method was evaluated by analyzing standard series of samples with 
concentrations ranging from 100 to 2000 ng/mL of ketamine in plasma and brain homogenates. 




the corresponding concentration of ketamine (expressed in ng/mL). The calibration curves 
were generated in Bruker QuantAnalysis (Bruker Daltonics, Bremen, Germany) using the least-
square linear regression method. The benchmark for the calibration range includes, the 
accuracy and precision of ketamine’s calibration to fall within  ±15% deviation (n = 6) as 
stipulated in the EMA guidelines for Bioanalytical Method Development as well as a 
correlation coefficient of  r ³0.99. 
2.6.3| Accuracy, precision and recovery 
Four QC levels were analyzed in order to determine the intra- and inter-day accuracy and 
precision parameters. The satisfactory percentage recovery standards and limit of variation on 
precision and accuracy should be within 15% of nominal values of the QC samples, LQC, 
MQC, HQC. In Accordance with the EMA guidelines the LLOQ (n = 6) should fall within 
20% of the nominal value.  
2.6.4| Stability Testing 
Due to the delay in injection of extracted samples, the stability of ketamine was investigated at 
the LQC, MQC and HQC under different conditions i.e bench-top stability for 6 hours at room 
temperature, autosampler stability for 24 hours and after three freeze-thaw cycles (-80°C).  
2.6.5| Sample Preparation 
Samples were prepared using 100 µl of biological sample (plasma/ brain homogenate) that was 
obtained from treated animals and were spiked with 7.5 µl of IS. 892,5µl of Ammonium 
Acetate (10mM, pH 9.5) was thereafter added to the analyte mixture consisting of IS and 
biological sample. The samples were mixed vigorously by a vortex mixer for 1 minute and then 
centrifuged at 10 000 rpm for 15 minutes at 4°C. Solid phase extraction (SPE) was performed 
using a C18-50mg, C18-100mg, Hydrophilic-Lipophilic-Balance and Hybrid Phospholipid 
Cartridges (HLB) (Sigma Aldrich, Germany). Briefly, cartridges were preconditioned with 1ml 
of MeOH and ammonium acetate followed by the sample. The cartridges were washed with 
ultrapure water and analyte was collected with MeOH in an autosampler vial for analysis. The 
same procedure was followed in the construction of calibration curves of the biological 
matrices; in which recoveries were investigated at three-quality control (QC) levels; the low 
quality control (LQC), middle-quality control (MQC) and high-quality control (HQC). The QC 





3| RESULTS AND DISCUSSION 
This LC-MS method developed in this study was suitable for the quantification of ketamine in 
rat plasma and brain tissues. Chromatographic separation was achieved with a retention time 
of 1.0 min for the both the target analyte and the IS at m/z 238.1 and 242.1 respectively; with 
an optimized collision energy of 12eV for both Ketamine and the IS. Positive ion mode 
exhibited preferable signaling of the target analyte to that of the negative ion mode. Separation 
was performed on an Ascentisâ Express Biphenyl column (5cm x 2.1 i.d., 2.7 µm Particle 
size) with a total run-time of 7 minutes. A recent study utilized a  CHIRAL-AGPâ MS (2.0 
mm i.d x 15cm ., 5 µm Particle size) column for the  chiral separation of ketamine and its 
enantiomers, however with significantly a longer run-time of 25 minutes [75].  
 
The calibration curves (n = 5) for quantification of ketamine maintained a linear range of 100 
to 2000 ng/ml in both plasma and brain homogenates. The linear equation of ketamine in 
plasma was y=0.895679x + 0.324036 with a R2³ 0.998; the brain homogenate linear equation 
was y=1.058604x + 0.462059 with a R2³ 0.999. The lower limit of quantification was 
100ng/mL which was determined by a S/N ³5 and a limit of detection (LOD) of 10ng/mL for 
both brain homogenate and plasma. 
The inter- and intra-day precision and accuracy in plasma and brain homogenates are presented 
in table 1 and 2. In plasma the intra- and inter-day precision ranged from 1,05 to 3,74%; 
whereas in brain homogenate it ranged from 0,65 to 2,20% with RSD values within the 
acceptable limits outlined by the EMA, with satisfactory percentage recovery standards and 
limit of variation on precision and accuracy falling within 15% of nominal values of the QC 
samples, LQC, MQC, HQC and the LLOQ falling within 20% of the nominal value. 
Table 1: Intra- and inter-day precision and accuracy of ketamine in plasma and brain homogenate(n=3 days) 
Plasma-Ketamine   
Quality control levels LLOQ LQC MQC HQC 
Concentration (ngmL-1) 100 250 750 2000 
Mean 98,45 244,85 721,48 1906,34 
Accuracy (%) 98,45 97,94 96,20 95,32 
Inter-day precision 
(R.S.D., %) 






1,05 1,35 1,26 3,74 
Brain-Ketamine   
Quality control levels LLOQ LQC MQC HQC 
Concentration (ngmL-1) 100 250 750 2000 
Mean 95,94 241,95 730,73 1957,22 
Accuracy (%) 95,94 96,78 97,43 97,86 
Inter-day precision 
(R.S.D., %) 
0,83 1,41 0,75 1,82 
Intra-day precision 
(R.S.D., %) 
2,20 1,35 0,65 1,80 
 
 
Table 2: Recoveries of Ketamine (n=3) from plasma and brain homogenate 
Plasma 
Concentration (ngmL-1) 100 250 750 2000      
 
64,85 61,24 58,68 60,07 
Recovery (%) 62,69 62,28 59,46 60,06  
65,71 62,90 59,98 59,45 
Mean (%) 64,42 62,14 59,37 59,86 
S.D. (%) 1,56 0,84 0,66 0,36 




Concentration (ngmL-1) 5 60 500 1500      
 
62,87 64,75 58,68 60,07 
Recovery (%) 64,43 64,68 59,46 60,06  
65,38 64,70 59,98 59,45 
Mean (%) 64,23 64,71 59,37 59,86 
S.D. (%) 1,27 0,03 0,66 0,36 





The autosampler, freeze-thaw and bench-top stability of Ketamine was evaluated at the LQC, 
MQC and HQC levels shown in Table 3. The results exhibit that the stability and recovery 
found in brain homogenate and plasma were within a range of 93,72-98,27% with a RSD of 
0,49-4,24% for the evaluated conditions. 
 
Table 3:Stability of Ketamine HCL in plasma and brain homogenate (n = 3)  
Ketamine Concentration ng/mL  
     
Bench-top stability added 
  
250 750 2000 
Plasma Found 
 
241,35 737,06 1912,75  
Accuracy % 
 
96,54 98,27 95,64  
RSD % 
 
2,99 1,51 3,53 
Brain Found 
 
243,44 714,62 1926,72  
Accuracy % 
 
97,37 96,34 96,34  
RSD % 
 
2,07 3,25 3,25       
Freeze-thaw stability Plasma Found 
 
241,15 722,36 1896,22  
Accuracy % 
 
96,46 96,31 94,81  
RSD % 
 
3,24 3,30 3,62 
Brain Found 
 
234,29 715,43 1910,28  
Accuracy % 
 
93,72 95,39 95,51  
RSD % 
 
0,49 4,24 4,05       
Autosampler stability Plasma Found 
 
238,26 729,92 1895,71  
Accuracy % 
 
95,30 97,32 94,79  
RSD % 
 
0,78 2,47 2,29 
Brain Found 
 
238,81 712,38 1926,53  
Accuracy % 
 
95,53 94,98 96,33  
RSD % 
 
0,46 0,96 2,34 
 
 
The Pharmacokinetic parameters of Ketamine (15mg/kg body weight),  were determined post 
IN, PO and IP administration in rat plasma and brain homogenates (Table 1) and Figures 14 
and 15. The pharmacokinetic parameters showed a Cmax of 524,58; 121,07 and 109,11 ng/mL 
and an AUC0-inf of 13059,65; 6785,37 and 5436,58 in plasma within following IP, IN and PO 
administration respectively (Figure 14).  
The purpose of this study was to compare the plasma and brain concentrations of ketamine 
following various routes of administration. The pharmacokinetic parameters showed a Cmax of 
352,06; 77,81 and 61,77 ng/g and an AUC0-inf of 10791,61; 2892,80 and 4060,70 in brain 




concentration in brain homogenate following PO and IN administration were below the limit 
of quantification of 100 ng/ml. 
Pharmacokinetic profiles of ketamine demonstrated that absorption is rapid in both plasma and 
brain homogenates with IP administration producing significantly higher plasma and brain 
concentrations to that of PO and IN administration. Oral bioavailability of ketamine is low due 
to extensive first-pass metabolism in the liver and intestine which can be compared to previous 
studies [19, 20], therefore this effect can be largely responsible for the low levels of ketamine 
observed in plasma and brain samples. Malinovsky et al. (1996) found that ketamine’s 
bioavailability in children was approximately 50% in plasma post IN administration and; 
therefore, the lowered ketamine levels following IN administration could be attributed to its 
moderate bioavailability [78]. This effect may be partly caused by substantial swallowing of 
relatively large intranasal depositions reducing its concentration in both the brain and plasma 
[76]. The Cmax reached was higher and reached quickly in both plasma and brain followed by 
a rapid decline until undetectable levels of ketamine were present 120 minutes post-
administration. It can therefore be concluded that IP administration exhibits more favorable 
concentrations in both brain tissue and plasma. 
 
 
Figure 14:Concentration-time profile of Ketamine in plasma(ng/mL) following a single dose of 15mg/kg to male Sprague 



























Figure 15:Concentration-time profile of ketamine in brain tissue(ng/g) following a single dose of 15mg/kg to male Sprague 
dawley rats via PO, IP, IN administration (n=3, mean±SD) 
Table 4: A summary of the pharmacokinetic parameters of Ketamine following a single dose of ketamine of 15mg/kg b.w 
Oral 
 Plasma Brain 
Cmax (ng/mL or ng/g) 109,11 61,77 
Tmax (min) 5 5 
T1/2 (min) 2,5 2,35 
Kel 0,0156 0,0060 




 Plasma Brain 
Cmax±SD (ng/mL or ng/g) 524,58 354,06 
Tmax (min) 5 5 
T1/2 (min) 15 2,55 
Kel 0,0126 0,0137 




 Plasma Brain 
Cmax±SD (ng/mL or ng/g) 149,29 77,81 
Tmax (min) 15 15 
T1/2 (min) 2,85 2,6 





























We developed a novel rapid and sensitive LC-MS method for the quantification of ketamine in 
rat plasma and brain homogenates in order to understand the effect of the route of 
administration on the brain concentration of ketamine for the treatment of major depressive 
disorder. We demonstrate that IN administration of ketamine is not be the ideal route of 
administration for drug delivery to the brain. However, future studies focused on the 
development of novel technologies that enhance its bioavailability may result in an easy to use 
IN formulation of ketamine for the treatment of MDD and TRD. Currently, parenteral 
administration of Ketamine exhibits more favorable brain drug delivery in order to produce 
satisfactory therapeutic outcomes when compared to IN and PO administration. Future 
investigations utilizing brain tissue imaging  are required in determining the brain distributions 
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CHAPTER 3: SUMMARY AND CONCLUSION 
The purpose of this study was to investigate the pharmacokinetics of ketamine in rat plasma 
and brain following administration of the same dose via different routes (IN, PO and IP). 
Ketamine was recently found to have excellent antidepressant activity aside from its analgesic 
and anaesthetic use in clinical practice. Almost two-thirds of patients with MDD do not obtain 
sufficient relief from conventional antidepressant treatments; and as many as one-third of these 
patients are categorized as treatment resistant. These patients remain untreated after numerous 
trials of antidepressants. In an attempt to resolve this increasing resistance to conventional 
antidepressants, medical practitioners have resorted to off-label use of ketamine for the 
treatment of MDD. However, a noteworthy problem was identified, that the route of 
administration significantly affected the pharmacokinetics of ketamine, especially in the brain, 
and is therefore a crucial consideration that needs to be taken when stabilizing a patient on a 
treatment regimen in order to ensure that optimum therapeutic levels are attained at the drug 
desired site. Many reports have been published on the IN efficacy of ketamine in the treatment 
of depression, however there have been no studies investigating the effects of the route of 
administration on drug delivery to the brain. 
In Chapter 1, it was emphasized that MDD is a debilitating mental disease, compromising the 
overall quality of everyday life of affected individuals. This also has a devastating impact on 
the public health system, based on the fact that this disorder has a more likely tendency to 
originate in adolescence and continue as a chronic or recurrent condition. MDD’s increasing 
prevalence has been associated with significant public health costs and morbidity rates; 
therefore, the effective treatment of the mental disorder is crucial. The findings of this study 
implicate future decisions on the use of ketamine and approaches to treat MDD in clinical 
practice.  
In Chapter 2, the study focused on the pharmacokinetics of ketamine by quantifying its 
concentration in plasma and the brain following a dose of 15mg/kg b.w after either oral, 
intranasal or intraperitoneal administration. Compared to previously reported studies of oral 
administrations, similar hindrances, due to low oral bioavailability were experienced due to 
extensive first pass metabolism in the liver and intestines. After oral administration ketamine’s 
concentrations were found to be below the limit of quantification in the brain, which is not 
ideal for the treatment of MDD. Intranasal administration is an alternative approach to 
administering ketamine due to its more favorable tolerability that has been reported; however 




compared to IM., IV and IP administration due to its diminished bioavailability. IP 
administration exhibited favorable concentrations as previously reported with a Cmax of 524,58 
and 352,06 ng/mL in plasma and brain tissue respectively.  
It is imperative that future studies centered on the use of ketamine for the treatment of MDD 
take into consideration the highlighted pharmacokinetic parameters, paving the way forward 
for the effective treatment of MDD, especially in those that have TRD. Future ketamine studies 
should be inclusive of brain distribution of ketamine with dosage forms and routes of 
administration that provide steady-state distribution of the drug; so that treatment regimens are 
centered at achieving the desired therapeutic outcomes. Studies should also focus on the 
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